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Abstract: Unravelling the complex molecular pathways responsible for motor neuron degeneration 16 
in amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) remains a persistent 17 
challenge. Interest is growing in the potential molecular similarities between these two diseases, 18 
with the hope of better understanding disease pathology for the guidance of therapeutic 19 
development. The aim of this study was to conduct a comparative analysis of published proteomic 20 
studies of ALS and SMA, seeking commonly dysregulated molecules to be prioritised as future 21 
therapeutic targets. Fifteen proteins were found to be differentially expressed in two or more 22 
proteomic studies of both ALS and SMA, and bioinformatics analysis identified 23 
over-representation of proteins known to associate in vesicles, and molecular pathways, including 24 
metabolism of proteins and vesicle-mediated transport; both of which converge on ER-Golgi 25 
trafficking processes. Calreticulin, a calcium-binding chaperone found in the ER, was associated 26 
with both pathways and we independently confirm that its expression was decreased in spinal 27 
cords from SMA and increased in spinal cords from ALS mice. Together, these findings offer 28 
significant insights into potential common targets that may help to guide the development of new 29 
therapies for both diseases. 30 
Keywords: spinal muscular atrophy; amyotrophic lateral sclerosis; proteomics; bioinformatics; 31 
ER-Golgi trafficking; calreticulin; CALR; endoplasmic reticulum; calcium 32 
 33 
1. Introduction 34 
The term “motor neuron disease” incorporates several conditions, including the most common 35 
adult form, amyotrophic lateral sclerosis (ALS), and the predominantly childhood form, spinal 36 
muscular atrophy (SMA); both of which represent a devastating cause of disability, morbidity and 37 
mortality. ALS is clinically characterised by muscular atrophy due to loss of motor neurons in the 38 
anterior horn of the spinal cord (“lower motor neurons”), and spasticity due to loss of cortical 39 
neurons (“upper motor neurons”) [1]. While approximately 90% of ALS cases occur sporadically 40 
(sALS), the remaining 10% of cases are attributable to a familial form of ALS (fALS) that typically 41 
follow an autosomal dominant inheritance pattern [2]. Genetic mutations have been identified 42 
accounting for half of the fALS cases, including mutations in the superoxide dismutase 1 (SOD1) 43 
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gene, the TAR DNA Binding protein-43 (TDP-43) gene, the fused-in-sarcoma (FUS) gene, and a 44 
hexonucleotide repeat within the C9orf72 gene [3]. SMA is also primarily characterised by loss of 45 
lower motor neurons and subsequent muscular atrophy, but without upper motor neuron 46 
involvement [4]. For >95% of SMA patients, the disease is caused by a loss-of-function defect in the 47 
SMN1 gene, resulting in reduced levels of the ubiquitously-expressed survival of motor neuron 48 
(SMN) protein [5].  49 
Unravelling the genetic basis of SMA and a proportion of ALS cases has been influential in 50 
guiding the direction of research, allowing for the development of animal models to further expand 51 
the study of motor neuron diseases. There is no cure for either disease, though some progress has 52 
been made in recent years towards the development of therapies that may extend survival or 53 
alleviate symptoms (reviewed for SMA [6], and for ALS [7]). Despite numerous clinical trials for ALS 54 
therapies, however, the only clinically approved treatments are riluzole, which may prolong 55 
survival by a modest 2-3 months, and edaravone, which was recently approved by the FDA to slow 56 
disease progression [8]. In 2017, nusinersen received clinical approval as the first antisense 57 
oligonucleotide gene therapy for SMA treatment. Clinical trial data suggests that treatment with 58 
nusinersen significantly improved disease symptoms for approximately 50% in patients with the 59 
most severe form of SMA (SMA Type I) [9,10], with a more modest effect in older patients [9–11]. 60 
There is a keen interest, therefore, to find alternative approaches to SMA and ALS therapy. For SMA, 61 
the need to tailor these treatments to the stage of development, the severity of disease, and to the 62 
effects of aging is widely recognised, but development has been hindered by lack of understanding 63 
of the mechanisms involved in disease pathogenesis and progression [6]. The disease mechanisms of 64 
ALS are likely to be even more complex, especially considering that approximately 90% of cases still 65 
have an unexplained etiology.  66 
Despite variation in the genetic basis of fALS and sALS, there is little difference recognised in 67 
their clinical presentation (aside from younger age at presentation in fALS) or any phenotypic 68 
pattern related to different genes [1,12]. This would suggest that the disease mechanisms of ALS 69 
likely converge on common molecular pathways, regardless of the etiology, that ultimately result in 70 
similar phenotypes. This then raises the question of whether there are core regulatory pathways 71 
involved in motor neuron disease pathology, in general, that may prove useful for guiding research 72 
into therapeutic development. Not unsurprisingly, therefore, the potential molecular similarities 73 
between ALS and SMA are receiving attention. Several recent reviews have discussed the current 74 
knowledge of pathways upon which both diseases appear to converge, including RNA processing 75 
pathways [13,14] and the TRAF6-nuclear factor kappa B (NF-κB) pathway [15]. Whilst these 76 
pathways certainly warrant further investigation, the precise molecular overlap between ALS and 77 
SMA is yet to be determined.  78 
Quantitative proteomics technology is well equipped to examine the complex molecular 79 
biology of both ALS and SMA and has been employed by research groups to study a range of cells 80 
and tissues from patients and animal models. Generation of these big datasets, however, has 81 
typically been followed by selection of several candidates for further examination, while most of the 82 
detected molecular changes have received little or no further attention. As a result, it is quite likely 83 
that important molecular changes have been overlooked, particularly at the level of molecular 84 
networks and pathways. Indeed, we previously interrogated published SMA proteomic datasets, 85 
and identified several proteins that were consistently dysregulated across multiple studies that had 86 
not previously been studied in association with SMA [16]. Importantly, this approach also 87 
highlighted conserved molecular responses to reduced SMN already proven to be directly relevant 88 
to SMA disease pathogenesis [16]. This provides confidence that multi-study comparison of 89 
proteomics data is a valid approach to finding disease-relevant targets for therapy design. 90 
Here, we have applied the same approach to interrogate a range of ALS proteomic datasets to 91 
gain new insights into mechanisms of disease pathogenesis. By systematically comparing the 92 
resulting pooled dataset with the previously published dataset of conserved molecular alterations in 93 
SMA [16] we highlight the core molecular overlap between both diseases and use bioinformatics 94 
tools to understand the pathways upon which they converge. In addition, we report that calreticulin, 95 
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a calcium-binding chaperone involved in the regulation of nascent protein folding [17], is associated 96 
with several perturbed pathways and we confirm that its expression levels are altered in spinal 97 
cords from both SMA and ALS mice. 98 
2. Materials and Methods 99 
2.1. Identification of ALS Proteomic Studies 100 
PubMed searches were performed to identify eligible studies for comparison, using 101 
combinations of the terms: “amyotrophic lateral sclerosis”, “Lou Gehrig’s disease” or “motor neuron 102 
disease” AND “proteomics” or “mass spectrometry”. The search was conducted to include studies 103 
published up to 1st July 2018, and published studies were considered eligible for inclusion if they had 104 
applied an unbiased proteomics approach to identify disease-specific protein patterns in ALS. 105 
Studies that utilised a targeted approach (i.e. seeking specific proteins) for initial protein 106 
identification were excluded. Initially 40 studies were eligible for review, but seven studies were 107 
further excluded from the list due to inaccessible or incomplete data (i.e. lack of access to complete 108 
article, only some results published or accessible), leaving 33 studies in total. Of these, 12 studies 109 
examined proteome changes in biofluids from ALS patients and 21 studies examined proteome 110 
changes in cells and tissues from ALS models (Table S1). 111 
2.2. Comparison of ALS Proteomic Studies 112 
The studies eligible for review applied a variety of strategies in data analysis and processing, 113 
and so it was therefore necessary to establish a method of data selection for the comparison. First, 114 
only proteins changed in expression in ALS compared to healthy controls were considered for 115 
analysis. Proteins that were differentially expressed between ALS and diseased controls (e.g. 116 
Alzheimer disease (AD)), protein changes identified between different groups of ALS patients, 117 
and/or protein changes identified between different regions of the same tissue were disregarded. 118 
Results from studies that used multiple groups in proteomic comparison were filtered so that only 119 
proteins that showed differential expression between ALS and healthy controls were included in the 120 
comparison. Proteomic datasets were first extracted into a Microsoft Excel spreadsheet. To facilitate 121 
an achievable and accurate method for comparison between the studies the protein identifiers from 122 
each study were then converted to official gene symbols using the Database for Annotation, 123 
Visualization and Integrated Discovery (DAVID 6.8) [18,19]. If protein identifiers were not provided, 124 
or if DAVID could not recognise the accession number, identifiers were assigned manually by 125 
searching for protein names using NCBI with the appropriate species filter to identify the 126 
corresponding accession number. Rarely, proteins had been removed from the NCBI database and 127 
so were not included in the final analysis. Most studies presented changes in the protein expression 128 
as a fold change (FC) difference between ALS and controls, after having applied a cut-off value to 129 
identify proteins that were differentially expressed in ALS. In cases where the cut-off value for fold 130 
change was not applied, only proteins that showed at least 20% change in the expression were 131 
included in the comparison. (This value was chosen because it has been commonly used in other 132 
published proteomic studies to identify differentially expressed proteins e.g. [20–22]). The final lists 133 
of gene names were then compared using Microsoft Excel’s ‘pivot table’ function to identify proteins 134 
that appeared in multiple studies. 135 
2.3. Bioinformatics Analysis 136 
The DAVID [18,19] platform was used to investigate the likely function of proteins that showed 137 
consistent change in expression across ALS studies. Gene ontology (GO) analysis was conducted to 138 
include terms that had at least three annotated proteins and a p-value ≤0.05. Redundant terms (i.e. 139 
those that were describing the same function and had identical matches, e.g. response to oxidative 140 
stress and removal of superoxide radicals) were combined into one term. STRING 10 [23] was used 141 
to identify statistically significant interactions between proteins that showed consistent change in 142 
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expression in ALS. Association network analysis was performed with high confidence (0.700) 143 
interaction score to exclude false positive results.  144 
2.4. Comparison of SMA and ALS Proteome Changes 145 
Differentially expressed proteins identified in the present ALS comparison (Table S2 – S5) were 146 
compared with the differentially expressed proteins identified in our previous multi-study 147 
comparison of SMA proteomic datasets [16] to investigate common molecular patterns between the 148 
two diseases. Proteins with dysregulated expression in both SMA and ALS datasets were subjected 149 
to bioinformatics analysis using DAVID [18,19] and STRING 10 [23] as described above. The 150 
Reactome curated database [24] was then used to explore functional relationships between proteins 151 
by analysing which pathways they map to and any known “reactions” within those pathways (i.e. 152 
individual steps in pathways that are known to change the state of a biological molecule). Reactome 153 
employs a binomial test to calculate the probability for each result, and p-values are corrected for the 154 
multiple testing using the Benjamini–Hochberg procedure. 155 
2.5. Animal Models 156 
For western blotting and immunohistochemistry experiments, the Taiwanese mouse model of 157 
severe SMA (Smn-/-; SMN2tg/o) on a congenic FVB background [25] and age-matched phenotypically 158 
normal controls (Smn+/-; SMN2tg/o) were obtained from breeding stock at the University of Edinburgh 159 
(Home Office license number PPL60/4569) and the ALS mouse model (SOD1G93A) [27] and 160 
20-week-old age/gender matched wild type (WT) littermates were obtained from the University of 161 
Oxford (Home Office number PDFEDC6F0). The breeding strategy, and genotyping using standard 162 
PCR protocols, were employed as previously described [26]. For quantitative PCR (qPCR) analysis, 163 
spinal cords were harvested from Taiwanese SMA (Smn-/-; SMN2tg/o) and control mice (Smn+/-; 164 
SMN2tg/o) as well as from 20-week-old SOD1G93A males and age/gender matched WT littermates 165 
housed at the University of Oxford (Home Office number PDFEDC6F0). All animal work was 166 
carried under the appropriate Project and Personal Licenses from the UK Home Office and following 167 
local ethical review. 168 
2.6. Western Blotting 169 
Spinal cords from postnatal day 8 (P8) SMA mice (n=5) and healthy littermate mice (n=5), and 170 
20 week-old ALS mice (n=5) and WT littermate mice (n=4) were left on ice for 15 minutes in 2X 171 
modified RIPA buffer (2% NP-40, 0.5% Deoxycholic acid, 2mM EDTA, 300 mM NaCl and 100 mM 172 
Tris-HCl (pH 7.4)), homogenised using pellet pestles and sonicated briefly 2-3 times every 10 173 
minutes. Samples were centrifugated at 13,000 RPM (Sanyo Scientific; MSB010.CX2.5) for 5 minutes 174 
at 4°C to pellet any insoluble material. Protein extracts were subjected to SDS-PAGE and western 175 
blotting. Briefly, samples were boiled in 2X SDS sample buffer (4% SDS, 10% 2-mercaptoethanol, 176 
20% glycerol, 0.125 M Tris-HCl (pH 6.8) and bromophenol blue) for 3 minutes at 95°C and subjected 177 
to SDS-PAGE (Biorad) using 4-12% Bis-Tris polyacrylamide gels (Invitrogen). A slice of the gel was 178 
excised and stained with Coomassie blue as an internal loading control for total protein. The 179 
proteins in the remaining part of the gel were transferred to nitrocellulose membrane by western 180 
blotting overnight. After blocking with 4% powdered milk in PBS for one hour, the membranes were 181 
incubated with rabbit anti-calreticulin antibody (Novus, NB600-103SS; 1:500) in dilution buffer (1% 182 
fetal bovine serum, 1% horse serum, 0.1% BSA in PBS with 0.05% Triton X-100) at room temperature 183 
for one hour, followed by incubation with HRP-labelled goat anti-rabbit Ig (DAKO, P0488) in 184 
dilution buffer at 0.25 ng/mL. Between each step membranes were washed three times with PBS for 185 
five minutes. Membranes were incubated with West Femto (Pierce) and visualised using a Gel 186 
Image Documentation system (Biorad). Densitometry measurements of antibody reactive bands 187 
were obtained using Fiji software (v1.51) [28] and were normalised to densitometry measurements 188 
of the Coomassie stained gel. For densitometry measurements only, contrast and brightness were 189 
adjusted uniformly across the gel and blot to decrease the background and enhance signal detection. 190 
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After first testing whether the data was normally distributed using a Shapiro-Wilk normality test, 191 
independent a two-tail t-test was used to determine whether there was a statistically significant 192 
difference between WT and ALS mice, and a Mann-Whitney U test was used to test for significant 193 
difference between healthy controls and SMA mice. All statistical analyses were performed in SPSS 194 
version 24 (IBM, New York, USA). 195 
2.7. Immunohistochemistry 196 
For immunohistochemistry, spinal cords from P8 SMA mice and healthy littermates, and 20 197 
week-old ALS mice and WT littermates were fixed in 4% PFA for 24 hours, followed by 198 
cryopreservation in 30% sucrose for another 24 hours. Lumbar spinal cord sections (25 μm) were 199 
permeabilised with 0.3% Triton X-100 in PBS for ten minutes and blocked for one hour in 4% 200 
BSA/PBS with 0.1% Triton X-100 or in 10% goat serum/PBS. After incubation with rabbit 201 
anti-calreticulin antibody (Abcam, EPR3924; 1:250) in blocking buffer (4% BSA/PBS with 0.1% Triton 202 
X-100 or 4% BSA/PBS with 0.1% Triton X-100 and 1% goat serum) overnight at 4°C, sections were 203 
incubated with goat anti-rabbit IgG Alexa Fluor 546 (Invitrogen; A11030) or goat anti-rabbit IgG 204 
Alexa Fluor 488 (Invitrogen; A11034) for one hour at 5 μg/mL, followed by DAPI staining (Sigma; 0.4 205 
μg/mL) for 10 minutes and mounted using Hydromount (National diagnostics). Between each step 206 
sections were washed with PBS three times for ten minutes. Images were obtained using Leica SP5 207 
confocal microscope with 63X oil immersion objective. Densitometry measurements of calreticulin 208 
staining in motor neurons of the anterior horn were performed using Fiji software (v1.51) [28]. First, 209 
images were calibrated using a calibrated step tablet. Rectangular selection that fills most of the step 210 
without overlapping another one was created to measure mean grey value of the first step. The same 211 
rectangular selection was then used to measure the mean grey value of all the consecutive steps in 212 
the tablet. Measured values were plotted against standard measurements of optical density (OD) to 213 
create a calibration curve. Prior to analysis, the mean OD of the negative control was subtracted from 214 
the image to correct the background. Calreticulin staining in the anterior horn of lumbar spinal cord 215 
sections was assessed in two control and two SMA mice (P8), and in two WT and two ALS mice (20 216 
weeks). A minimum of four sections from each mouse were used in the analysis. Fields of view were 217 
selected from each section, and measurements of three distinct regions that contained alpha motor 218 
neurons were taken from each field of view using a rectangular selection tool of fixed size. A 219 
minimum of 45 measurements were made from each experimental group. Statistical analysis was 220 
performed in SPSS version 24 (IBM, New York, USA). The Shapiro-Wilk test was used to assess the 221 
distribution of quantitative data, followed by a Mann-Whitney U test to determine whether there 222 
was a statistically significant difference in calreticulin staining between control and SMA mice, and 223 
between WT and ALS mice. 224 
2.8. Quantitative PCR 225 
Spinal cords were harvested from P7 SMA mice and healthy littermates as well as from 226 
20-week-old SOD1G93A males and age/gender matched WT littermates. RNA was extracted with the 227 
RNeasy MiniKit (Qiagen). Reverse transcription was performed using the High-Capacity cDNA 228 
Reverse Transcription Kit (Applied Biosystems) for spinal cords from SMA and control mice. For 229 
ALS and WT mice, reverse transcription was performed using the qPCRBIO cDNA Synthesis Kit 230 
(PCR Biosystems). qPCRs were performed using qPCRBIO SyGreen Blue Mix Hi-ROX (PCR 231 
Biosystems). Primers were as follows: PolJ F: ACCACACTCTGGGGAACATC; PolJ R: 232 
CTCGCTGATGAGGTCTGTGA; Calreticulin F: AAGACTGGGATGAACGAGCCAAGA; 233 
Calreticulin R: AATTTGACGTGGTTTCCACTCGCC. RNA polymerase II polypeptide J (PolJ), was 234 
used as a validated housekeeping gene as it has previously been demonstrated as being stably 235 
expressed between tissues and in different pharmacological conditions [29]. Relative gene 236 
expression was quantified using the Pfaffl method [30] and primer efficiencies were calculated with 237 
the LinRegPCR software. Statistical analysis was performed in SPSS version 24 (IBM, New York, 238 
USA). The Shapiro-Wilk test was used to test normality, followed by independent two-tail t-tests to 239 
determine whether there was a statistically significant difference between groups. 240 
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3. Results 241 
3.1. Overview of ALS Proteomic Studies 242 
A total of 33 proteomic studies of ALS were eligible for comparison (Table S1) [20,31–62]. As 243 
expected, the number of differentially expressed proteins identified in studies correlated with the 244 
sensitivity of the method used, with label-free technologies having identified by far the greatest 245 
number of protein changes compared to 2D-gel approaches. Both in-vivo and in-vitro models of ALS 246 
were used in analyses, and samples from animal models and ALS patients were equally represented 247 
across studies (Table S1). Samples were derived from a range of sources, including ALS patient 248 
cerebrospinal fluid (CSF) [20,31–40], patient serum [41], a range of cell models [42,44,57,59], ALS 249 
patient muscle [45,46], ALS patient blood mononuclear cells (PBMC) [48], ALS patient spinal cord 250 
[61], ALS patient prefrontal cortex [62], and tissues/cells from various mouse and rat models of ALS 251 
including astrocytes [47], skeletal muscle [53], ventral roots [50], embryonic motor neurons [51], 252 
spinal cord [43,49,52,54–56,58], and hippocampus [60]. 253 
3.2. Multi-Study Proteomic Identification of Conserved Molecular Response in ALS Patients and ALS 254 
Experimental Models 255 
Protein expression changes in biofluids may not necessarily correlate with protein changes at 256 
the cellular level and may in fact be contradictory. It is possible that secretion or leakage of proteins 257 
into the CSF or serum may, for example, be accompanied by a concomitant decrease of expression 258 
levels in tissues [63]. Thus, studies that utilised cells/tissues were compared separately to those that 259 
examined biofluids. Comparison across the 12 proteomic studies that examined biofluids from ALS 260 
patients [20,31–41] identified 11 proteins that were consistently changed in the same direction across 261 
at least two studies (Table S2). Of these, one protein – cystatin C - was decreased in expression across 262 
four separate studies [35,37–39] and one protein – chitinase 3-like protein 1 - was increased in 263 
expression across three separate studies [32,34,41]. The remaining eight proteins showed opposing 264 
directions of differential expression (Table S3). Gene ontology (GO) analysis was performed using 265 
the DAVID software [18,19] to investigate the likely function of the 11 proteins that showed a 266 
consistent change in expression. “Establishment of localization” was the most enriched biological 267 
process term, with seven of the eleven proteins mapping to it (Figure S1A), and complementary to 268 
this, 9 of the 11 proteins were associated with the term “vesicles”; eight of which were connected to 269 
the term “extracellular vesicles” (Figure S1B). STRING 10 analysis identified association network 270 
between four proteins: HBA1, HP, TF and ORM1 (Figure S1D), all of which appear to be 271 
plasma-derived proteins. 272 
Comparison of the 21 studies that investigated proteome changes in tissues and cells from ALS 273 
patients and animal models identified 80 proteins that were differentially expressed across two or 274 
more studies. Of these, 42 proteins showed a consistent direction of differential expression (Table 275 
S4), eleven of which were upregulated across three or more studies: aldolase A [47–49,53,57], 276 
superoxide dismutase 1 [53,54,56] and 2 [44,48,52,58], 14-3-3 protein gamma [44,52,54], calreticulin 277 
[44,48,50], glyceraldehyde-3-phosphate dehydrogenase [49,53,54], heatshock protein 1 [44,54,56], 278 
heatshock protein family A member 8 [44,48,54], peroxiredoxin 2 [44,48,51] and 6 [48,49,56] and glial 279 
fibrillary acidic protein [47,54,62]. The remaining 38 proteins showed a contradictory direction of 280 
expression in different studies (Table S5).  281 
STRING 10 analysis of the 42 proteins that showed a consistent change in expression revealed 282 
strong association between mitochondrial and endoplasmic reticulum proteins that are involved in 283 
the control of energy homeostasis, oxidative stress response and protein homeostasis (Figure 1A and 284 
Table S6). Within the networks, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was found 285 
to have the greatest number of known associations, linking with proteins involved in each of the 286 
three main domains. GO analysis of the 42 proteins using the DAVID platform supported these 287 
findings and highlighted enrichment of additional terms including programmed cell death, muscle 288 
tissue development and synaptic signaling (Figure 1B and Table S6). Cellular component GO 289 
analysis returned a range of terms, but similar to the bioinformatics finding from the CSF studies, 290 
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the greatest number (i.e. 64%) of annotated proteins were associated with the term “extracellular 291 
vesicles” (Figure 1C). Enriched terms in the domain “molecular function” were predominantly 292 
associated with binding activity (Figure 1D).  293 
 294 
Figure 1. Bioinformatics analysis of the proteins consistently changed in the same 295 
direction in ALS tissues and cells. A) STRING 10 association network showing only the 296 
proteins that demonstrated association. The type of association between proteins is 297 
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indicated by the colour (pink: experimentally determined interactors; light blue: 298 
interactors form curated database; grey: protein homology; black: co-expression; yellow: 299 
text-mining; dark blue: gene co-occurrence; green: gene neighbourhood). Three functional 300 
groups of proteins associated with regulation of oxidative stress, energy homeostasis and 301 
protein homeostasis were identified in the network from Figure 1B. GO term analysis 302 
using the DAVID platform revealed enriched terms connected to B) biological processes, 303 
C) cellular component and D) molecular function. The top 10 terms from each domain are 304 
presented as bars. White numbers inside the bars indicate number of annotated proteins. 305 
The full list of terms together with annotated proteins is available in Table S6. 306 
3.3. Multi-Study Proteomic Identification of Conserved Molecular Perturbations in both SMA and ALS 307 
To identify conserved protein changes common to SMA and ALS, differentially expressed 308 
proteins identified in the ALS multi-study comparison (Table S2 – S5) were compared with the 309 
differentially expressed proteins identified in our previous multi-study comparison of SMA 310 
proteomic datasets [16]. The following fifteen proteins were found to be differentially expressed in 311 
both diseases and are summarised in Figure 2: calreticulin [21,44,48,50,64], superoxide dismutase 1 312 
[53,54,56,65–67], aldolase fructose-bisphosphate A [22,47–49,53,57,65,66], heat shock protein family 313 
D, member 1 [22,44,58,65,66], peroxiredoxin 2 [44,48,51,66,67], voltage dependent anion channel 1 314 
[47,52,57,64,66], vimentin [21,44,47,54,64], phosphoglycerate kinase 1 [22,48,49,60,66], annexin A5 315 
[52,54,66,68], heat shock protein 90 beta family member 1 [47,54,64,66], glyceraldehyde-3-phosphate 316 
dehydrogenase  [49,53,54,65–67], heat shock protein HSP 90 alpha [22,44,54,64,65], ATP synthase 317 
subunit alpha mitochondrial [22,47,54,57,60,66], 14-3-3 protein gamma [22,44,52,54,66,68], 2,3-cyclic 318 
nucleotide 3-phosphodiesterase [44,52,64]. 319 
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 320 
Figure 2. Proteins differentially expressed in both SMA and ALS proteomic studies. A) 321 
Venn diagram showing the number of proteins differentially expressed in SMA proteomic 322 
studies compared to ALS proteomic studies. Fifteen of those proteins were identified in 323 
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both SMA and ALS comparison. B) Heat map of proteins that were differentially expressed 324 
in both SMA and ALS proteomic studies. Protein names are presented as official gene 325 
symbols. The reference for each study is given in the corresponding squares of the heat 326 
map. Experimental model and sample type used in each study are indicated above the 327 
table. ALDOA- aldolase, fructose-bisphosphate A; ANXA5- annexin A5; ATP5A1- ATP 328 
synthase subunit alpha mitochondrial; CALR- calreticulin; CNP- 2,3-cyclic nucleotide 329 
3-phosphodiesterase; GAPDH- glyceraldehyde-3-phosphate dehydrogenase; HSP90AA1- 330 
heat shock protein HSP 90 alpha; HSP90B1- heat shock protein 90 beta family member 1; 331 
HSPD1- heat shock protein family D, member 1; PGK1- phosphoglycerate kinase 1; 332 
PRDX2- peroxiredoxin 2; SOD1- superoxide dismutase 1; VDAC1- voltage dependent 333 
anion channel 1; VIM- vimentin; YWHAG- 14-3-3 protein gamma. 334 
Programmed cell death was one of the most enriched biological process GO terms (Figure 3A) 335 
and is likely describing the downstream consequences of disease pathogenesis. Other highly 336 
enriched terms included regulation of immune system, regulation of protein metabolism, 337 
cytoskeleton organization, metabolism of reactive oxygen species. Strikingly, all fifteen proteins 338 
identified in the comparison were associated with the cellular component term “extracellular 339 
vesicles” (Figure 3B). Transport and establishment of localization were also among enriched 340 
biological process GO terms (Figure 3A). Enriched terms in the domain “molecular function” were 341 
associated with binding activity (Figure 3C). String 10 analysis revealed a strong association network 342 
between 14 of the 15 proteins (Figure 3D). 343 
 344 
Figure 3. Bioinformatics analysis of the fifteen proteins differentially expressed in both 345 
SMA and ALS proteomic studies. Gene ontology analysis revealed enriched terms 346 
connected to A) biological process, B) cellular component and C) molecular function. In the 347 
biological process domain, only terms with five or more annotated proteins are presented. 348 
Terms are presented as bars, with the white numbers inside the bars indicating number of 349 
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annotated proteins. The full list of terms together with annotated proteins is available in 350 
Table S7. D) String 10 association network of proteins that were differentially expressed in 351 
SMA and ALS. Proteins connected to metabolic function, oxidative stress response and 352 
protein stability were identified in the network from Figure 3A. The type of the association 353 
between proteins is indicated by the colour (pink: experimentally determined interactors; 354 
light blue: interactors form curated databases; grey: protein homology; black: 355 
co-expression; yellow: text-mining; dark blue: gene co-occurrence; green: gene 356 
neighbourhood).  357 
Reactome pathway analysis [24] was performed to further explore which pathways the 15 358 
proteins dysregulated in both ALS and SMA are associated with. At the genome-wide view, 359 
pathways that were over-represented were largely complementary to those identified by the GO 360 
analysis, above (Figure 4A). Of the over-represented pathways identified, only two – “metabolism of 361 
proteins” and “vesicle-mediated transport” - were shown to have a direct connection to each other 362 
(Figure 4B) [69]. The molecular highway connecting these two pathways is the “endoplasmic 363 
reticulum (ER) to Golgi anterograde transport” pathway [69], suggesting this as a core pathway 364 
upon which ALS and SMA disease mechanisms converge. Of particular note is that calreticulin 365 
(CALR) was associated with both “metabolism of proteins” and “vesicle-mediated transport” 366 
pathways (Figure 4B) and was the only protein identified with a consistent direction of differential 367 
expression across SMA and ALS proteomic studies (Figure 2B). 368 
 369 
Figure 4. Reactome analysis of the fifteen proteins differentially expressed in both SMA 370 
and ALS proteomic studies. A) Genome-wide overview of Reactome pathway analysis 371 
identified several over-represented pathways (highlighted using a coloured scale on the 372 
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right-hand side that indicates false discovery rate (FDR)), including ER to Golgi 373 
anterograde transport [69], B) Zoomed view of “metabolism of proteins” and 374 
“vesicle-mediated transport” pathways. Over-represented pathways are indicated by the 375 
red line. Proteins annotated to each pathway are shown. 376 
3.4. Calreticulin Expression is Dysregulated in Spinal Cord Tissue from ALS and SMA Mice 377 
None of the five proteomic studies that analysed whole spinal cord extracts from mouse or rat 378 
models of ALS reported detection of calreticulin [49,52,54–56] (Table S1) (but this is perhaps not 379 
surprising since each of these studies utilised a 2D-gel electrophoresis protocol which identifies 380 
significantly fewer proteins compared to more recent techniques such as iTRAQ or label-free 381 
quantification). Though iPS-derived motor neurons have been studied in the context of SMA [64], 382 
there have been no proteomic studies of spinal cord or primary motor neurons isolated from animal 383 
models of SMA to date. We therefore performed quantitative western blot analysis of spinal cord 384 
extracts from mouse models of ALS (SOD1G93A) and SMA (severe ‘Taiwanese’ model) at late 385 
symptomatic time-points to determine the expression levels of calreticulin relative to healthy 386 
littermate controls. In spinal cord extracts from ALS mice, calreticulin expression was significantly 387 
increased by an average of 43% (p=0.003) (Figure 5A). In contrast, however, calreticulin expression in 388 
SMA spinal cord extracts was significantly reduced by 22% compared to that of controls (p=0.004) 389 
(Figure 5B). Immunohistochemistry analysis of the ventral horn of lumbar spinal cord sections from 390 
control and age-matched (P8) SMA mice closely aligned with the quantitative western blotting, 391 
showing calreticulin was reduced by an average of 26% in SMA compared to controls (p<0.001) 392 
(Figure 5C). A significant difference in calreticulin expression was not detected by 393 
immunohistochemistry analysis of ALS and WT lumbar spinal cord sections (Figure 5C), but 394 
RT-PCR analysis of calreticulin gene expression aligned with the trends seen by western blot results, 395 
showing a statistically significant increase in ALS vs WT (Figure 5D) and a slight, but statistically 396 
significant, decrease in SMA vs control spinal cords (Figure 5E). 397 
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 398 
Figure 5. Dysregulated expression of calreticulin in spinal cord extracts from 399 
late-symptomatic ALS mice (20 week) and late-symptomatic SMA mice (P8). 400 
Representative western blots showing A) a 43% increase in calreticulin (CALR) expression 401 
levels in spinal cords of ALS mice (n=4) compared to wild type (WT) mice (n=5); B) a 26% 402 
reduction of calreticulin expressin in SMA mice (n=5) compared to control mice (n=5). 403 
Graphs are presented as integrated density of measured protein normalised to total 404 
protein (Coomassie stained gel). Densitometry measurements for individual samples and 405 
mean of the group are shown, with error bars showing standard error from the mean; C) 406 
Representative immunohistochemistry images showing calreticulin expression in the 407 
ventral horn of lumbar spinal cord sections in 20-week old WT and ALS mice and in 408 
control and age-matched (P8) SMA mice. Scale bar = 50 μm. Densitometry measurements 409 
of calreticulin levels in alpha motor neurons are presented as mean optical density, with 410 
error bars showing standard error from the mean.; D) Calreticulin gene expression levels in 411 
WT and ALS mice, and; E) in control and SMA mice, as determined by RT-PCR. Expression 412 
levels of calreticulin were normalized to PolJ. Error bars represent standard error from the 413 
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mean. CALR- calreticulin; CTR- control; WT – wild type. Ns-not significant; *p<0.05; ** 414 
p<0.01; ***p<0.001 415 
4. Discussion 416 
Here, we used a comparative approach to identify core molecular perturbations shared 417 
between SMA and ALS with the aim of understanding common molecular mechanisms of disease 418 
pathogenesis. Multi-study comparisons of published proteomic datasets identified 15 proteins that 419 
were dysregulated across two of more separate studies in both SMA and ALS. These proteins 420 
therefore represent a potential “molecular fingerprint” of disease pathogenesis that is shared 421 
between both diseases. Bioinformatics analysis of the 15 differentially expressed proteins identified 422 
over-representation of several pathways including cell death, protein metabolism and 423 
vesicle-mediated transport pathways; with the latter two being linked via the ER to Golgi 424 
anterograde transport pathway. One of the 15 proteins, calreticulin, was strongly associated with 425 
this pathway because of its involvement with both protein metabolism and vesicle-mediated 426 
transport pathways [69,70]. Using quantitative western blot and immunohistochemistry, we 427 
demonstrated for the first time that calreticulin is reduced in expression in spinal cords from 428 
late-symptomatic SMA mice, and in agreement with proteomic studies of other ALS cells and tissue 429 
[44,48,50], we measured increased levels of calreticulin in spinal cord extracts from symptomatic 430 
ALS SOD1G93A mice.  431 
Golgi fragmentation and ER stress were both identified as key pathological features in sALS 432 
[71] and transgenic mouse models of fALS [72], and both were evident at a pre-symptomatic stage of 433 
disease, directly implicating them in disease pathogenesis [72,73]. It was only recently, however, by 434 
studying induced pluripotent derived-motor neurons from SMA patients, that ER stress was 435 
implicated in SMA pathogenesis [74]. In line with this, ER stress was also found to be a prominent 436 
feature of spinal motor neurons from a mouse model of X-linked spinal and bulbar muscular 437 
atrophy [75], and alterations of Golgi apparatus were previously reported in anterior horn cells from 438 
patients with X-linked spinal and bulbar muscular atrophy [76] and in fibroblasts from patients with 439 
a rare autosomal dominant form of SMA [77].  440 
ER stress and Golgi alterations can both be triggered by impaired ER-Golgi transport 441 
mechanisms, ultimately leading to induction of the cell death-related pathways [78,79]. 442 
Dysregulated protein transport between ER and Golgi, identified in the bioinformatics analysis here, 443 
therefore highlights the possibility that the same biological mechanism is responsible for aspects of 444 
disease pathogenesis in SMA and ALS. Indeed, ALS-associated mutant SOD1, TDP-43 and FUS 445 
proteins have been reported to inhibit ER-Golgi trafficking in neuronal cells [78,80]. Importantly, 446 
dysregulation of ER-Golgi trafficking preceded protein aggregation, ER stress, Golgi fragmentation 447 
and axon degeneration in NSC-34 cells expressing mutant SOD1 [78], and dysregulated ER-Golgi 448 
trafficking was observed as an early event in embryonic cortical and motor neurons in a mouse 449 
model of ALS [80]. Over-expression of Rab1, a master regulator of ER-Golgi transport, restored 450 
ER-Golgi trafficking and prevented induction of ER stress, formation of intracellular aggregations 451 
and apoptosis in in vitro model of ALS [80]. Several studies also indicate a role for defective ER-Golgi 452 
transport in SMA. SMN interacts with α-COP, a member of COPI vesicles that mediates ER-Golgi 453 
transport [81–84], and knockdown of α-COP caused SMN accumulation in Golgi apparatus of 454 
neuron-like NSC34 cells [82] and produced developmental defects in motor neuron-like NSC34 cells 455 
and primary cortical murine neurons [84]. Over-expression of human α-COP reversed motor neuron 456 
defects in SMN-depleted NSC34 cells [83,84] and in motor neurons from a zebrafish model of SMA 457 
[84]. A role for defective ER to Golgi transport in ALS and SMA pathogenesis is further supported by 458 
our finding here that all fifteen of the differentially expressed proteins, common to SMA and ALS, 459 
mapped to “extracellular vesicles” in cellular compartment GO analysis. 460 
Calreticulin is a multifunctional protein involved in a range of processes, including the 461 
regulation of Ca2+ homeostasis in the ER, chaperone activity in secretory pathways, folding of 462 
nascent proteins, regulation of immune system, and modulation of cell adhesion [17]. Its chaperone 463 
activity in the ER is dependent on calcium (Ca2+) levels and perturbations in Ca2+ homeostasis can 464 
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disrupt the correct functioning of protein folding machinery [85]. It has been suggested that 465 
defective Ca2+ handling is responsible for triggering calreticulin depletion in ALS vulnerable motor 466 
neurons, leading to ER stress and apoptosis [86]. In addition, defects in Ca2+ handling have been 467 
demonstrated in both SMA [87–89] and ALS [90–92]. Alterations in calcium homeostasis are also 468 
known to inhibit ER-Golgi trafficking [93], indicating a possible common mechanism that drives ER 469 
and Golgi defects in SMA and ALS. Calreticulin was previously identified from proteomic studies as 470 
having increased levels in iPS-derived motor neurons from type I SMA patients [64] and in SMA 471 
mouse muscle [21], and this was verified biochemically in muscles from SMA mice and SMA 472 
patients [21]. In contrast, we observed a statistically significant decrease of calreticulin levels in 473 
spinal cord extracts from late symptomatic mice. In proteomic studies of ALS, calreticulin was found 474 
to be increased in the ventral roots from the spinal cord of ALS SOD1G93A mice [50], blood 475 
mononuclear cells from ALS patients [48], and in TDP-43 knockdown SH-SY5Y cells [44], and in 476 
agreement with this, we also found increased levels of calreticulin in spinal cord extracts from 477 
late-symptomatic ALS SOD1G93A mice. This is, however, in contrast with a biochemical study of 478 
lower motor neurons isolated from ALS SOD1G93A mice that reported decreased expression of 479 
calreticulin [86].  480 
When taken together, there is certainly evidence to support a role for calreticulin dysregulation 481 
in both ALS and SMA, but it is important too, to consider possible explanations for the opposing 482 
patterns of calreticulin expression reported in different studies, as this may offer further insights into 483 
disease mechanisms. In the case of whole spinal cord from ALS mice, for example, differences in 484 
calreticulin expression in different cell populations could, according to a theory proposed by 485 
Bernard-Marissal et al. [86], have contributed to the overall calreticulin expression levels, masking 486 
changes that were previously reported to be specific to vulnerable lower motor neurons [86]. This 487 
could also offer an explanation for why western blotting and RT-PCR analysis of whole spinal cord 488 
extracts revealed a statistically significant increase in calreticulin protein and gene expression in 489 
ALS, but immunohistochemistry analysis of lumbar spinal cord sections did not. It has been shown 490 
that calreticulin levels increase under stress conditions prior to being secreted to the cell surface; a 491 
process that is associated with the functional role of calreticulin in apoptosis [94]. It is thus possible 492 
that opposing directions of perturbed calreticulin expression reflect ongoing cycles of apoptosis in 493 
vulnerable motor neurons. The time-course of disease is another potential variable to consider, since 494 
Bernard-Marissal et al. [86] studied ALS mice up to 110 days of age, compared to the later time-point 495 
of 140 days in the present study. The obvious limitations of using a late-symptomatic animal model 496 
is that it cannot determine whether changes in protein expression levels are causative of disease 497 
pathology or are simply reflective of cell death processes. It would be of interest, therefore, to verify 498 
the expression of calreticulin throughout different stages of disease development in both SMA and 499 
ALS and determine whether other cell populations in proximity of vulnerable motor neurons or 500 
unaffected spinal cord regions contribute to alterations in calreticulin levels. Further work is clearly 501 
warranted too, to examine the relationship between calreticulin perturbations, defective Ca2+ 502 
handling, and ER and Golgi defects in SMA and ALS, and whether targeting these pathways offers a 503 
potential therapeutic approach to both diseases. 504 
In this study we demonstrated that calreticulin expression is altered at both the transcript and 505 
protein level in ALS and SMA, so we were interested to determine the extent to which the other 506 
proteomic changes common to ALS and SMA can be traced back to aberrant gene regulation. None 507 
of the SMA and ALS proteomic studies used in this comparison also investigated changes using 508 
transcriptomics approaches, but a small number of transcriptomic studies of SMA and ALS have 509 
been conducted separately using comparable experimental models. For ALS, two transcriptomic 510 
studies investigated gene alterations in patient blood mononuclear cells [95,96], but none of the four 511 
proteins found to be differentially expressed in the proteomic study (Table 2) were reported to be 512 
differentially expressed at the gene level in either of the two studies. One of the eight proteins that 513 
were differentially expressed in spinal cords from ALS SOD1G93A mice [54] (Figure 2), ATP5A1, was 514 
also found to be differentially expressed at the gene level in a separate study [97]; with both 515 
proteomic and transcriptomic studies having reported an increased expressed in ALS. For SMA, two 516 
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proteins were differentially expressed in mouse embryonic stem cell (ESC)-derived motor neurons 517 
(Figure 2) [68], and one of these – ANXA5 – was also found to be differentially expressed in a 518 
separate transcriptomics study [98], but with the opposite direction of change. None of the five 519 
proteins differentially expressed in iPSC-derived motor neurons from Type I SMA patients (Figure 520 
2) [64] were found to be differentially expressed in a transcriptomics study of similar cell lines [74]. 521 
The altered expression of calreticulin (verified in this study at both transcript and protein level), and 522 
the altered expression of ATP5A1 protein levels (Figure 2) [22,47,54,57,60,66] and at the transcript 523 
level in a separate transcriptomic study [97], suggest that these molecular changes could be due to 524 
aberrant gene transcription. The majority of well-characterised molecular changes in SMA and in 525 
many fALS cases, however, have been traditionally attributed to dysregulation of RNA metabolism 526 
[14], and the apparent lack of overlap between the profile of differentially expressed proteins 527 
summarised in this study with differentially expressed genes found in separate studies supports that 528 
possibility that at least some changes may be due to post-transcriptional gene regulation defects. 529 
Perturbed post-transcriptional gene regulation in both diseases have been associated with several 530 
defective RNA processing pathways, including those that regulate RNA splicing [99], RNA stability 531 
and translation [100,101]. A growing body of evidence also suggests physical and functional links 532 
between SMA and ALS-associated proteins, including SMN, FUS, TDP43 and SOD1, some of which 533 
are RNA-binding proteins (summarised in recent reviews [14,15]). This may also offer an 534 
explanation of how perturbations in RNA processing pathways extend to fALS cases with mutations 535 
in non-RNA binding proteins such as SOD1 [14]. Taken together, it seems that aberrant 536 
post-transcriptional gene regulation might contribute to some, but perhaps not all, of the molecular 537 
defects in SMA and ALS. Further work is clearly warranted though to establish the precise 538 
relationship between ALS and SMA transcriptional and post-transcriptional changes and protein 539 
expression changes. When doing so, it will be important to consider these relationships in the same 540 
cell / tissue type, matched for both relative age and disease timeline.  541 
The aim of this study was to identify the molecular overlap between SMA and ALS, but it is 542 
important not to overlook the results from the comparative analysis of ALS proteomic data sets 543 
(Table S2-5) as these are likely to provide a useful resource for research aimed at understanding 544 
ALS-specific pathways and biomarkers. Whilst several of these proteins have gained significant 545 
attention in the context of ALS, including the putative auxiliary biomarker, cystatin C [102] and 546 
SOD1 [15], several proteins appear to have been overlooked when these data sets were considered in 547 
isolation. One such protein, aldolase A, for example, was increased in expression in five separate 548 
studies of ALS cells and tissues [47–49,53,57]. Given its importance in glycolysis [103], 549 
overexpression of this protein is highly likely to reflect perturbed metabolic activity. Indeed, 550 
mitochondrial dysfunction [104] and ER stress [105] are known early pathological features and a 551 
major contributing factor of motor neuron death in ALS. Not surprisingly, most of the dysregulated 552 
proteins identified in tissues and cells from ALS patients and models were associated with energy 553 
homeostasis, oxidative stress response and control of protein stability, confirming the importance of 554 
ER and mitochondria in ALS disease pathways. Recently, defective ER-mitochondria crosstalk has 555 
received attention in the context of ALS pathogenesis, implying that ER and mitochondria 556 
perturbations cannot be perceived separately, but rather as a complex network of changes that 557 
together contribute to ALS pathogenesis [106,107]. This therefore presents an opportunity for the 558 
development of therapeutic approaches for ALS to simultaneously target functional defects in the 559 
ER and mitochondria [106,107]. 560 
Another important finding is that most proteins with a consistent direction of differential 561 
expression across ALS proteomic studies were associated with extracellular vesicles. Significant 562 
attention has been given to extracellular vesicles in the context of neurodegenerative disorders, 563 
including ALS, as a potential source of biomarkers and as a possible mechanism of misfolded 564 
protein spreading in CNS [108]. Mutant SOD1 and TDP-43 proteins are among molecules whose 565 
prion-like properties, facilitated by exosome transport, are thought to contribute to spreading of 566 
protein misfolding in ALS [108]. Interestingly, all fifteen proteins identified in both ALS and SMA 567 
were also associated with extracellular vesicles. A recent study reported increased levels of 568 
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exosomes in culture media from SMN-depleted cells, SMA patient fibroblasts, and in serum from 569 
SMA patients and mouse model of SMA [109], indicating alterations in exosome transport as another 570 
shared link between SMA and ALS. 571 
To conclude, we provide evidence that integrating multi-study comparisons of proteomic 572 
datasets with bioinformatics analysis can help to unravel complex disease mechanisms. The fifteen 573 
proteins identified here represent the core molecular overlap between SMA and ALS; many of 574 
which, have not until now, been considered in isolation. The identification of over-represented 575 
pathways, including two that converge on ER-Golgi trafficking, offers further insights into 576 
mechanistic cross-talk between SMA and ALS. Together, these findings offer significant insights into 577 
potential common targets that may help to guide the development of new therapies for both 578 
diseases. 579 
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